{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"19.9","value":"7.3"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"19.6","value":"3.8"},{"groupId":"OG002","lowerLimit":"10.7","upperLimit":"44.9","value":"25.0"},{"groupId":"OG003","lowerLimit":"13.8","upperLimit":"50.2","value":"29.6"},{"groupId":"OG004","lowerLimit":"2.7","upperLimit":"32.4","value":"12.5"},{"groupId":"OG005","lowerLimit":"23.4","upperLimit":"63.1","value":"42.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"description":"Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort A.\n\nParticipants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort B.","id":"OG000","title":"Cohort A and B"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A2"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort E"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least one dose of the study drug. Per Protocol, Cohort A and B participants \\[Gastric-GEJ cancer (Second-Third L)\\] were combined and outcome data was analyzed under a single arm (Cohort A and B).","reportingStatus":"POSTED","timeFrame":"Baseline to Measured Progressive Disease (Up to 24 Months)","title":"Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}